Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer

References

• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin.55(1), 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Kiemeney lA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J. Urol.150(1), 60–64 (1993).
   PubMed Web of Science ®Google Scholar
• Prout GR Jr, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J. Urol.148(5), 1413–1419 (1992).
   PubMed Web of Science ®Google Scholar
• Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br. J. Urol.80(5), 762–765 (1997).
   PubMedGoogle Scholar
• Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J. Urol.163, 60–61 (2000).
   PubMed Web of Science ®Google Scholar
• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol.164, 680–684 (2000).
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Solsona E, Akaza H et al. Low-grade Ta urothelial carcinoma of the bladder. Urology66(S6), 75–89 (2005).
   PubMed Web of Science ®Google Scholar
• Shelley MD, Kynaston H, Court J et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. Br. J. Urol. Int.88, 209–216 (2001).
   Google Scholar
• Allard P, Bernard P, Fradet Y, Tetu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br. J. Urol.81(5), 692–698 (1998).
   Google Scholar
• Kurth KH, Denis L, Bouffioux C et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur. J. Cancer31A(11), 1840–1846 (1995).
   Google Scholar
• Brandau S, Bohle A. Bladder cancer. Molecular and genetic basis of carcinogenesis. Eur. Urol.39(5), 491–497 (2001).
   PubMed Web of Science ®Google Scholar
• Williams SG, Stein JP. Molecular pathways in bladder cancer. Urol. Res.32(6), 373–385 (2004).
   PubMed Web of Science ®Google Scholar
• Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat. Clin. Pract. Urol.2(10), 502–510 (2005).
   PubMedGoogle Scholar
• Goessl C, Knispel HH, Miller K, Klan R. Is routine excretory urography necessary at first diagnosis of bladder cancer? J. Urol.157(2), 480–481 (1997).
   PubMed Web of Science ®Google Scholar
• Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. Long-term followup of a bladder carcinoma cohort: routine followup urography is not necessary. J. Urol.160(1), 45–48 (1998).
   PubMed Web of Science ®Google Scholar
• Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology66(S6), 4–34 (2005).
   PubMed Web of Science ®Google Scholar
• Sauter G, Algaba F, Amin M et al. Non-invasive urothelial neoplasias. WHO classification of non-invasive papillary urothelial tumors. In: World Health Organization Classification of Tumors. Eble JN, Sauter G, Epstein JI, Sesterhenn I (Eds). IARCC Press, Lyon, France 89–157 (2004).
   Google Scholar
• Jichlinski P, Leisinger HJ. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist! Urol. Int.74(2), 97–101 (2005).
   PubMed Web of Science ®Google Scholar
• Krieg RC, Fickweiler S, Wolfbeis OS, Knuechel R. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem. Photobiol.72(2), 226–233 (2000).
   PubMed Web of Science ®Google Scholar
• Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J. Urol.168(1), 67–71 (2002).
   PubMed Web of Science ®Google Scholar
• Kriegmair M, Zaak D, Rothenberger KH et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J. Urol.168(2), 475–478 (2002).
   PubMed Web of Science ®Google Scholar
• Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, Phase III multicenter study. J. Urol.174(3), 862–866 (2005).
   PubMed Web of Science ®Google Scholar
• Daniltchenko DI, Riedl CR, Sachs MD et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J. Urol.174(6), 2129–2133 (2005).
   PubMed Web of Science ®Google Scholar
• D’Hallewin MA, Kamuhabwa AR, Roskams T, De Witte PA, Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. Br. J. Urol. Int.89(7), 760–763 (2002).
   Google Scholar
• Kausch I, Bohle A. Bladder cancer. II. Molecular aspects and diagnosis. Eur. Urol.39(5), 498–506 (2001).
   PubMed Web of Science ®Google Scholar
• Van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur. Urol.47(6), 736–748 (2005).
   PubMed Web of Science ®Google Scholar
• Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology66(S6), 64–74 (2005).
   PubMed Web of Science ®Google Scholar
• Dyrskjot L, Thykjaer T, Kruhoffer M et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet.33(1), 90–96 (2003).
   PubMed Web of Science ®Google Scholar
• Dyrskjot L, Zieger K, Kruhoffer M et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin. Cancer. Res.11(11), 4029–4036 (2005).
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol.41(5), 523–531 (2002).
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology60(5), 822–824 (2002).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden A, Witjes JA et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology66(S6), 90–107 (2005).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49, 466–477 (2006).
   PubMed Web of Science ®Google Scholar
• Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J. Urol.170(3), 964–969 (2003).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol.171, 2186–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol.168, 1964–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol.174(1), 86–91 (2005).
   PubMed Web of Science ®Google Scholar
• Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason MD. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst. Rev.3, CD003231 (2003).
   PubMedGoogle Scholar
• Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. Br. J. Urol. Int.93(4), 485–490 (2004).
   Google Scholar
• Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J. Clin. Epidemiol.53, 676–680 (2000).
   PubMed Web of Science ®Google Scholar
• Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res.21, 765–769 (2001).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am. J. Clin. Oncol.26(4), 402–407 (2003).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am. J. Clin. Oncol.27(5), 522–528 (2004).
   PubMed Web of Science ®Google Scholar
• Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol.169, 90–95 (2003).
   PubMed Web of Science ®Google Scholar
• Böhle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology63(4), 682–686 (2004).
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish–Norwegian Bladder Cancer Study Group. J. Urol.161, 1124–1127 (1999).
   PubMed Web of Science ®Google Scholar
• de Reijke TM, Kurth KH, Sylvester RJ et al. European Organization for the Research and Treatment of Cancer-Genito-Urinary Group. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). J. Urol.173, 405–409 (2005).
   PubMed Web of Science ®Google Scholar
• Bouffioux C, Kurth KH, Bono A et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J. Urol.153(3 Pt 2), 934–941 (1995).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W et al. The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur. Urol.44(4), 423–428 (2003).
   PubMed Web of Science ®Google Scholar
• Tolley DA, Parmar MK, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J. Urol.155(4), 1233–1238 (1996).
   PubMed Web of Science ®Google Scholar
• Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br. J. Urol.79(5), 731–735 (1997).
   PubMedGoogle Scholar
• Conrad S, Friedrich MG, Schwaibold H et al. Long term prophylaxis with mitomycin C further reduces tumor recurrence compared to short term prophylaxis with MMC or bacillus Calmette–guérin (BCG). J. Urol.171, 71 (2004).
   Google Scholar
• Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al. Has a 3-fold decreased dose of bacillus Calmette-guerin the same efficacy against recurrences and progression of T1G3 and Cis bladder tumors than the standard dose? Results of a prospective randomized trial. J. Urol.174, 1242–1247 (2005).
   PubMed Web of Science ®Google Scholar
• Patard J, Moudouni S, Saint F et al. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology58(4), 551–556 (2001).
   PubMed Web of Science ®Google Scholar
• Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol.166(4), 1296–1299 (2001).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med.325(17), 1205–1209 (1991).
   PubMed Web of Science ®Google Scholar
• Herr HW, Laudone VP, Badalament RA et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol.6(9), 1450–1455 (1988).
   PubMed Web of Science ®Google Scholar
• Anderstrom C, Johansson S, Nilsson S. The significance of lamina propria invasion on the prognosis of patients with bladder tumors. J. Urol.124(1), 23–26 (1980).
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand. J. Urol. Nephrol.21(3), 185–195 (1987).
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19, 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Peyromaure M, Zerbib M. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. Br. J. Urol. Int.93(1), 60–63 (2004).
   Google Scholar
• Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. Eur. Urol.45(6), 730–735 (2004).
   PubMed Web of Science ®Google Scholar
• Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J. Urol.172(1), 70–75 (2004).
   PubMed Web of Science ®Google Scholar
• Nseyo UO, DeHaven J, Dougherty TJ et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J. Clin. Laser Med. Surg.16, 61–68 (1998).
   PubMedGoogle Scholar
• Morgan J, Lottman H, Abbou CC, Chopin DK. A comparison of direct and liposomal antibody conjugates of sulfonated aluminum phthalocyanines for selective photoimmunotherapy of human bladder carcinoma. Photochem. Photobiol.60, 486–496 (1994).
   PubMed Web of Science ®Google Scholar
• Stenzl A, Eder I, Kostron H, Klocker H, Bartsch G. Electromotive diffusion (EMD) and photodynamic therapy with δ-aminolaevulinic acid (δ-ALA) for superficial bladder cancer. J. Photochem. Photobiol. B36, 233–236 (1996).
   PubMed Web of Science ®Google Scholar
• Kriegmair M, Baumgartner R, Lumper W, Waidelich R, Hofstetter A. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br. J. Urol.77, 667–671 (1996).
   PubMedGoogle Scholar
• Waidelich R, Beyer W, Knuchel R et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology61, 332–337 (2003).
   PubMed Web of Science ®Google Scholar
• Marti A, Jichlinski P, Lange N et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J. Urol.170, 428–432 (2003).
   PubMed Web of Science ®Google Scholar
• Kamuhabwa A, Agostinis P, Ahmed B et al. Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder. Photochem. Photobiol. Sci.3, 772–780 (2004).
   PubMed Web of Science ®Google Scholar
• Skyrme RJ, French AJ, Datta SN, Allman R, Mason MD, Matthews PN. A Phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. Br. J. Urol. Int.95(9), 1206–1210 (2005).
   Google Scholar
• Irie A. Advances in gene therapy for bladder cancer. Curr. Gene Ther.3(1), 1–11 (2003).
   PubMedGoogle Scholar
• Smith AD, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J. Urol.169, 1219–1228 (2003).
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Keyhani A, Williams D et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a Phase I study of p53 gene therapy. J. Clin. Oncol.21, 2247–2253 (2003).
   PubMed Web of Science ®Google Scholar
• Ardelt P, Kausch I, Böhle A. Gene and antisense therapy of bladder cancer. Adv. Exp. Med. Biol.539, 155–158 (2003).
   PubMed Web of Science ®Google Scholar
• Harimoto K, Sugimura K, Lee CR, Kuratsukuri K, Kishimoto T. In vivo gene transfer methods in the bladder without viral vectors. Br. J. Urol.81, 870–874 (1998).
   PubMedGoogle Scholar
• Kuball J, Wen SF, Leissner J et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. Oncol.20, 957–965 (2002).
   PubMed Web of Science ®Google Scholar
• Siemens DR, Austin JC, See WA, Tartaglia J, Ratliff TL. Evaluation of gene transfer efficiency by viral vectors to murine bladder epithelium. J. Urol.165, 667–671 (2001).
   PubMed Web of Science ®Google Scholar
• Loskog A, Hedlund T, Wester K et al. Human urinary bladder carcinomas express adenovirus attachment and internalization receptors. Gene Ther.9, 547–553 (2002).
   PubMed Web of Science ®Google Scholar
• Glackin AJ, Gray SB, Johnston SR, Duggan BJ, Williamson KE. Antisense oligonucleotides in the treatment of bladder cancer. Expert Opin. Biol. Ther.5, 67–77 (2005).
   PubMed Web of Science ®Google Scholar
• Blietz C, Kausch I, Doehn C, Kynast B, Jocham D. Distribution and effectivity of Ki-67 antisense oligonucleotides after intravesical application in a bladder cancer model. Presented at: AUA Annual Meeting, Atlanta, Abstract 92065 (2006).
   Google Scholar
• van der Heijden AG, Kiemeney LA, Gofrit ON et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur. Urol.46, 65–71 (2004).
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol.21, 4270–4276 (2003).
   PubMed Web of Science ®Google Scholar
• Moskovitz B, Meyer G, Kravtzov A et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann. Oncol.16(4), 585–589 (2005).
   PubMed Web of Science ®Google Scholar
• Watkin NA, Morris SB, Rivens IH, Woodhouse CR, ter Haar GR. A feasibility study for the non-invasive treatment of superficial bladder tumours with focused ultrasound. Br. J. Urol.78, 715–721 (1996).
   PubMedGoogle Scholar
• Wang GM, Yang YF, Sun LA, Xu ZB, Xu YQ. An experimental study on high intensity focused ultrasound combined with mitomycin treatment of bladder tumor. Zhonghua Wai Ke Za Zhi41, 897–900 (2003).
   PubMedGoogle Scholar
• Vallancien G, Harouni M, Guillonneau B, Veillon B, Bougaran J. Ablation of superficial bladder tumors with focused extracorporeal pyrotherapy. Urology47, 204–207 (1996).
   PubMed Web of Science ®Google Scholar
• Riedl CR, Knoll M, Plas E, Pfluger H. Electromotive drug administration and hydrodistention for the treatment of interstitial cystitis. J. Endourol.12, 269–272 (1998).
   PubMed Web of Science ®Google Scholar
• Colombo R, Brausi M, Da Pozzo L et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion. Eur. Urol.39, 95–100 (2001).
   PubMed Web of Science ®Google Scholar